These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication? van de Loosdrecht AA; Westers TM; Ossenkoppele GJ Leuk Res; 2008 Feb; 32(2):205-7. PubMed ID: 17714781 [No Abstract] [Full Text] [Related]
34. Consensus statement on iron overload in myelodysplastic syndromes. Bennett JM; Am J Hematol; 2008 Nov; 83(11):858-61. PubMed ID: 18767130 [TBL] [Abstract][Full Text] [Related]
35. [Myelodysplastic syndromes: clinically relevant aspects in diagnosis, prognosis and prediction]. Noesslinger T; Pfeilstoecker M Dtsch Med Wochenschr; 2008 Oct; 133(41):2086-90. PubMed ID: 18985562 [No Abstract] [Full Text] [Related]
36. World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromes. Schiffer CA Semin Hematol; 2008 Jan; 45(1):3-7. PubMed ID: 18179963 [TBL] [Abstract][Full Text] [Related]
38. Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials. Mo A; McQuilten ZK; Wood EM; Weinkove R Intern Med J; 2017 Jun; 47(6):695-698. PubMed ID: 28580745 [TBL] [Abstract][Full Text] [Related]
39. Unraveling the mysteries of MDS: linking science to practice through case studies. Oestreicher P ONS Connect; 2007; 22(8 Suppl):61-2. PubMed ID: 17824569 [No Abstract] [Full Text] [Related]
40. Incremental gains and a long road ahead in MDS. Steensma DP; Tefferi A Oncology (Williston Park); 2008 Nov; 22(12):1352, 1358, 1360. PubMed ID: 19320067 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]